A case of primary lymphoma of the bladder managed with multimodal therapy

Horasanlı, Kaya; Kadıhasanoğlu, Mustafa; Aksakal, Öznur; Ozagari, Aysim; Miroğlu, Cengiz

doi:10.1038/ncpuro1035

Cited by 18 publications

(30 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The base for disease development in these cases is still unknown. Other authors have raised the possibility of a residual embryonic cloaca, from which the bladder derives, source lymphoid proliferation in adulthood [15].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…MALT-lym-lymphomas [7]; CHOP was reported by the literature to be the most frequently applied [5,15,20,28]. It has documented success in treating both low and high grade primary bladder lymphomas as either solitary treatment or combination therapy [15]. The addition of rituximab in cases of CD20 positivity should be systematic due to the therapeutic benefit provided by this monoclonal antibody in this situation [10,28,33].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Case Report about a Primary Bladder Lymphoma

Combaz¹,

Kühn²

2017

Int Arch Urol Complic

View full text Add to dashboard Cite

Primary isolated bladder lymphoma represents around 0.2% of all extranodal Non-Hodgkin-Lymphoma and less than 1% of all bladder tumours. Clinical representation may be unspecific and correct diagnosis is essential for the appropriate treatment. We expose the case of a patient with a primary B-cell bladder lymphoma with normal cystoscopy. Case report:A 67-year-old patient presented with lower urinary tract infections, overactive bladder with urinary incontinence as well as haematuria susceptible for bladder carcinoma. Urine sediment, cytologie, abdominal-and kidney ultrasound as well as a CT scan did not lead to a conclusive diagnosis. Surprisingly, cystoscopy did not demonstrate any tumourous lesions and urine cytology revealed free of malignant cells. Cold four-quadrant cut biopsies finally did reveal the presence of a primary B-cell lymphoma. After a four weeks' antibody treatment of Rituximab (Mabthera) the patient showed subjective improvement and lower urinary tract symptoms disappeared. Clinical follow-up as well as repeat cystoscopic biopsies were undertaken every six months. After a follow-up period of nearly three years the patient is still in complete remission. Urinary tract infections and incontinence as well as OAB symptoms disappeared entirely.Discussion: Haematuria was the main clinical finding in the current case of primary bladder lymphoma. Uneventful radiologic examinations lead to the necessity of bladder biopsies without any macroscopic pathologic findings. We present the exceedingly rare case of a primary bladder lymphoma without any characteristic lesions in the bladder lumen. For this reason, cystoscopic four quadrant biopsies should be used largely. Biopsies are essential leading to the correct diagnosis and finally successful treatment. Single antibody therapy with Rituximab is an option in selected cases as the one presented and can be used as un therapeutic option.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Case Report about a Primary Bladder Lymphoma

Combaz¹,

Kühn²

2017

Int Arch Urol Complic

View full text Add to dashboard Cite

show abstract

“…5,6,8 The major symptoms are intermittent haematuria, dysuria and urinary frequency. The tumour occurs 6.5 times more frequently in women than in men and the mean age of affected patients is 64 years (range 20 − 85 years).…”

Section: Discussionmentioning

confidence: 99%

“…4 Most primary bladder lymphomas are B-cell lymphomas. 5,6 The present case report describes the clinical features, imaging and laboratory findings, and the treatment of a patient with primary T-cell lymphoma of the bladder.…”

Section: Introductionmentioning

confidence: 99%